Bruker (BRKR)
Health Care · Scientific and Analytical Instruments · NASDAQ
Bruker provides advanced analytical and diagnostic technology platforms that enable scientific breakthroughs in life sciences, materials research, and clinical applications.
What Bruker does
Bruker Corporation develops, manufactures, and distributes high-performance scientific instruments and high-value analytical and diagnostic solutions. Its products enable researchers and industrial customers to explore life and materials at microscopic, molecular, and cellular levels. The company operates through a portfolio of specialized technology segments focused on life science research, pharma, applied markets, and advanced diagnostics.
Themes: Life science research tools, Analytical instrumentation, Precision microscopy, Clinical diagnostics, Materials science research, Pharma/Biotech R&D tools
Fundamentals
- Price$59.56 as of 2026-08-21 close
- Market cap$9.0B as of 2026-08-21
- 1-year return+76.2% 2025-08-21 close $33.80 → 2026-08-21 close $59.56
- P/En/a negative earnings
- Net margin-2.0% as of 2026-08-24
- Gross margin+47.7% as of 2026-08-24
- ROE-2.9% as of 2026-08-24
- Debt / equity0.77 as of 2026-08-24
- Revenue growth (YoY)+1.6% as of 2026-08-24
- Revenue CAGR (3y)+10.7% SEC XBRL
- Beta1.24 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.3%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How BRKR compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldbottom 10% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
BRKR is not currently in any published Top 10 list. Its scores are below.
Long-term score
42.4 #758 of 987 scored · #45 of 57 in Health Care
Long-term trend 74th (over the past 12 months this stock beat the market by 55.7 percentage points) and capital return 71st (consecutive years of dividend increases 5 years); weakest is profitability (5th, operating margin -1.5%, return on equity -2.9%).
Short-term score
48.4 #899 of 1,704 scored · #158 of 240 in Health Care
Momentum 63rd: over the past 3 months this stock beat the market by 29.3 percentage points; trend 63rd: the price is 8% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; weakest is setup 25th: no fresh 20-day breakout up or down.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, BRKR's dividend was covered by reported results (free-cash-flow payout 53%). This describes past coverage, not a forecast.
- Earnings payoutnot assessable earnings were not positive that year
- Free-cash-flow payout53% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Bruker looks technically
Bruker (BRKR) is trading 27.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 55 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day low about 14 trading days ago.
Trend
7
| Distance from the 200-day | it is trading 27.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +27.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $58.47 | $58.47 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $46.91 | $46.91 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 55 trading days ago — a "golden cross", a bullish long-term signal | 55 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend) | 19.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30) | 53.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($48.63 to $61.84) — its "stochastic" reading is 83 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 82.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $65.30 | $65.30 |
|---|---|---|
| From the 52-week high | it is 8.8% below its 52-week high (its highest price of the past year) | -8.8% |
| Above the 52-week low | it is 108.8% above its 52-week low (its lowest price of the past year) | +108.8% |
| Below the 52-week high | it is 8.8% below its highest point of the past year | 8.8% |
| Since a 20-day breakout | it made a new 20-day low about 14 trading days ago | 14 sessions |
| Since a 55-day breakout | it made a new 55-day high about 17 trading days ago | 17 sessions |
| All-time high | its highest closing price on record is $94.86 (set on 2024-03-21) | $94.86 |
| Given back of the 52-week move | over the past year its closes ranged ($29.35 to $64.34), and it has given back only a small part of its rise from last year’s low — 14% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $41.60 to $42.72. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 13.7% |
| From the all-time high | it is 37.2% below its all-time high | -37.2% |
| Nearest price level | it is sitting right on a support level at $59.45 — a price it turned at twice since 2024-11-25, most recently on 2025-01-31. Since 2024-08-21 it has 14 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.2% |
| All-time low | its lowest closing price on record is $3.07 (set on 2008-11-21) | $3.07 |
| Above the all-time low | it is 1840.1% above its all-time low | +1,840% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 61st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.11 between its high and its low — about 5.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.11 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $50.30 and $66.16 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $50.30 – $58.23 – $66.16 |
| Typical daily range (% of price) | its price moves about 5.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.2% |
| Stretch from the 200-day average | it is trading 4.1 daily ranges above its 200-day average price (27.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.45× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|---|---|
| Open gap | it gapped 15.9% below the previous close 13 sessions ago and has not traded back through the level it left behind at 64.31 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -15.9% |
| Gap filled | a 2.7% gap down opened on 2026-08-20 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 3.8 percentage points (the stock lost 1.4% while the market gained 2.3%) | -3.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 29.3 percentage points (the stock gained 32.4% while the market gained 3.1%) | +29.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 44.5 percentage points (the stock gained 55.6% while the market gained 11.1%) | +44.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 55.7 percentage points (the stock gained 76.2% while the market gained 20.5%) | +55.7% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.2% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 16.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +1.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 24% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $47.89 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +24.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% above the average price paid since it last reported on 2026-08-04 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $54.92 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | +8.4% |
Price levels it has turned at before
BRKR last closed at $59.56 on 2026-08-21. Since 2024-08-21 it has turned at 14 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $59.45 | Support | 0.2% below the last close | turned there twice · 2024-11-25 to 2025-01-31 |
| $61.62 | Resistance | 3.5% above the last close | turned there three times · 2024-09-11 to 2026-07-15 |
| $62.95 | Resistance | 5.7% above the last close | turned there twice · 2024-11-06 to 2026-07-01 |
| $56.08 | Support | 5.8% below the last close | turned there twice · 2026-01-12 to 2026-07-08 |
| $54.61 | Support | 8.3% below the last close | turned there five times · 2024-11-05 to 2026-07-21 |
| $64.83 | Resistance | 8.8% above the last close | turned there three times · 2025-01-13 to 2026-07-31 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · beating the market · Printed a doji candle · At the top of its 14-day range (stochastic above 80) | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.08 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$58.75 range $40.00 – $70.00; median $60.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BRKR
- Consensus EPS estimate$0.4174 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Exposure to global economic conditions and fluctuations in research and development spending by customers.","Dependence on international sales, making the company susceptible to foreign currency exchange rate volatility and geopolitical risks.","Complexity of integrating acquired businesses and potential for future goodwill or asset impairment charges."]
What changed in the latest 10-Q
AI-assisted comparison of BRKR's 10-Q filed 2026-05-07 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Form 10-K for year ended December 31, 2025 (older filing referenced December 31, 2024)
- Newer filing presents financial data for three months ended March 31, 2026 and 2025 (older filing presented three and nine months ended September 30, 2025 and 2024)
- Newer filing shows revenue of $823.4M for Q1 2026 vs $801.4M for Q1 2025
- Newer filing shows Operating Income of $10.2M for Q1 2026 vs $31.8M for Q1 2025
- Newer filing shows Net cash provided by operating activities of $71.2M for Q1 2026 vs $65.0M for Q1 2025
- Newer filing includes Non-GAAP Organic Revenue decrease of (4.4)% year-on-year for Q1 2026
- Removed:
- Older filing reference to current U.S. government shutdown and its impacts on company business removed from newer filing
- Older filing reference to One Big Beautiful Bill Act (OBBBA) removed from newer filing
- Older filing reference to potential governmental investigations involving regulatory and marketing practices removed from newer filing
- Older filing reference to potential energy shortages in Europe removed from newer filing
- Older filing nine-month period financial data removed (newer filing shows only three-month periods)
- Older filing references to 'conflicts in the Middle East' changed in newer filing to 'conflicts in the Middle East and surrounding areas and hostilities involving Iran'
- Reworded:
- Older filing stated 'additional tariffs, including those imposed or that may be imposed or changed by the presidential administration' changed to 'additional tariffs, including those imposed or that may be imposed or changed by the current presidential administration' in newer filing
- Older filing stated 'the conflict in the Middle East and surrounding areas' changed to 'conflicts in the Middle East and surrounding areas and hostilities involving Iran' in newer filing
- Older filing stated 'our working capital requirements and sufficiency of cash to fund our operations' changed to 'our working capital requirements and the sufficiency of our cash, borrowings and proceeds of indebtedness to fund our operations and investment activities' in newer filing
- Overview section: older filing stated 'manufacturer, and distributor' changed to 'manufacturer and distributor' in newer filing (comma removed)
- Overview section: older filing stated 'we maintain major research and development and manufacturing centers in Europe, Asia and North America, and we have commercial offices' changed to same in newer filing with identical structure
- Notes:
- The two filings cover different periods (Q1 2026 vs Q3 2025) and reference different fiscal year-end Form 10-Ks, making direct comparison of comparable periods limited
- The newer filing excerpt appears truncated at the Non-GAAP Financial Measures section, potentially limiting full assessment of all changes in the MD&A section
- Some removals in the newer filing may reflect period-specific issues (government shutdown, energy shortages) that were no longer relevant rather than substantive policy changes
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 2 sells ($230020) — 1 selling insider
- Last 180 days0 buys · 5 sells ($468500) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-15. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BRKR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding BRKR as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 31,451,875
- Reported value $1,136,234,927
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
BRKR had 12,684,689 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for BRKR because the newest share count we hold predates that settlement by more than 180 days, and a buyback or issuance in between would move the base. The reported figures above are unaffected.
- Reported short interest (shares) 12,684,689
- Prior settlement (shares) 14,632,119
- Reported change -13.31%
- Days to cover (reported) 6.55
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Thermo Fisher Scientific (TMO)
- Danaher Corporation (DHR)
- Agilent Technologies (A)
- Waters Corporation (WAT)
- PerkinElmer (PKI)
- Shimadzu Corporation
- JEOL Ltd.
- Oxford Instruments
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BRKR vs…
Bruker is found in…
Frequently asked questions
What does Bruker (BRKR) do?
Bruker Corporation develops, manufactures, and distributes high-performance scientific instruments and high-value analytical and diagnostic solutions. Its products enable researchers and industrial customers to explore life and materials at microscopic, molecular, and cellular levels. The company operates through a portfolio of specialized technology segments focused on life science research, pharma, applied markets, and advanced diagnostics.
What sector is Bruker (BRKR) in?
Bruker (BRKR) is classified in the Health Care sector. Its industry is Scientific and Analytical Instruments. It trades on NASDAQ.
Does BRKR pay a dividend?
Yes — Bruker (BRKR) pays a dividend, with an indicated yield of about 0.30% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Bruker's (BRKR) competitors?
Notable peers of Bruker (BRKR) include Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, Waters Corporation and PerkinElmer. This peer set is informational only — not financial advice.
Is Bruker (BRKR) overbought or oversold right now?
Bruker (BRKR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 53, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BRKR come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.